U.S. Tobacco Stock News

Vanda Pharmaceuticals (VNDA) is back on investors’ radar after the U.S. Food and Drug Administration approved BYSANTI tablets for bipolar I disorder and schizophrenia, while an earlier imsidolimab filing for generalized pustular psoriasis also progresses through review. See our latest analysis for Vanda Pharmaceuticals. The recent FDA approvals and filings have coincided with sharp share price moves, with a 37.31% 7 day share price return and 56.23% 90 day share price return, while the 1 year...

Why Palvella Therapeutics Has Caught Investor Attention Recent trading in Palvella Therapeutics (PVLA) has drawn attention after a sharp share price move, with the stock closing at US$128.60 and posting very large 1 year total returns. That type of performance, together with reported annual revenue growth of 63.12% and net income growth of 54.52% on a net loss of US$32.37 million, is prompting investors to reassess how they view this clinical stage biopharmaceutical name. See our latest...

AXIS Capital Holdings (NYSE:AXS) announced the retirement of board member Thomas Ramey. His retirement represents a change in the company’s board-level governance structure. For you as an investor, board changes at an insurer like AXIS Capital Holdings matter because they sit close to decisions on risk appetite, capital allocation and long term priorities. The company operates in specialty insurance and reinsurance, areas that can be influenced by evolving regulation and changing views on...

Allison Transmission Holdings (ALSN) closed out FY 2025 with Q4 revenue of US$737 million and basic EPS of US$1.19, alongside net income of US$99 million that sets the tone for how investors read the full year. The company has seen quarterly revenue move from US$824 million in Q3 2024 to US$814 million in Q2 2025, US$693 million in Q3 2025 and then US$737 million in Q4 2025. Basic EPS shifted from US$2.30 to US$2.32, US$1.63 and US$1.19 over the same stretch, giving a clear read on how top...

If you are wondering whether M/I Homes is still good value after a strong multi year run, this article walks through how its current share price stacks up against several valuation measures. The stock closed at US$140.40 recently, with returns of 4.8% over 30 days, 9.8% year to date and 17.9% over 1 year. The 3 year return sits at a very large 138.7%, and the 5 year return at 180.7%. Recent coverage of M/I Homes has focused on its position within the U.S. homebuilding sector and how...

Over the past few years, Quanex Building Products has experienced a significant drop in operating margin, earnings per share, and return on invested capital despite continuing to grow its revenue base. This combination of rising costs and weaker profitability on a per‑share and invested‑capital basis points to mounting operational pressures and fewer attractive growth opportunities within the business. Next, we’ll examine how this sustained margin deterioration challenges Quanex’s earlier...

Illinois Tool Works (NYSE:ITW) has entered into a new US$3.0b five year revolving credit facility. The agreement replaces the company’s previous revolving credit facility more than a year before its scheduled expiry. The facility includes multi currency and rate options and can be increased to up to US$5b, subject to conditions. Illinois Tool Works, a diversified industrial manufacturer serving multiple end markets, now has a refreshed liquidity backstop that can support its ongoing...

HP (HPQ) has opened Q1 2026 with revenue of US$14.4b and basic EPS of US$0.59, putting fresh numbers on the table for investors tracking how the story is evolving. The company has seen quarterly revenue move from US$14.1b in Q4 2024 to US$13.5b in Q1 2025 and US$14.4b in Q1 2026, while basic EPS has shifted from US$0.94 to US$0.60 and now US$0.59, setting a clear earnings run rate for the latest quarter. With these results in hand, the focus now turns to what they signal about HP's margin...

The Morning Bull - US Market Morning Update Thursday, Feb, 26 2026 US stock futures are mixed this morning, with S&P 500 contracts slightly softer while Nasdaq 100 and Dow futures hold near flat, as investors weigh stronger global growth signals against interest rate worries. Taiwan just reported a record current account surplus of about US$69.9b, powered by a US$63.6b goods trade surplus tied to AI and electronics exports, which underlines how demand for chips and hardware is feeding into...

If you are looking at Shoals Technologies Group and wondering whether the current share price reflects its true value, this article will walk you through what the numbers are saying in plain terms. The stock last closed at US$6.85, with returns of a 36.2% decline over 7 days, a 26.1% decline over 30 days, a 24.6% decline year to date, a 76.8% gain over 1 year, a 72.8% decline over 3 years and a 79.8% decline over 5 years, which gives a mixed picture of recent and longer term...

Iovance Biotherapeutics (NasdaqGM:IOVA) reported encouraging clinical trial data for lifileucel in patients with advanced sarcoma. The company plans to initiate a registrational trial and pursue accelerated FDA approval for lifileucel in this sarcoma setting. Iovance also received FDA Fast Track designation for lifileucel in non-small cell lung cancer. Iovance Biotherapeutics focuses on developing tumor infiltrating lymphocyte (TIL) therapies for difficult-to-treat cancers. The new sarcoma...

Early Comstock Resources investor Dallas C. Salazar has launched a new family office, Two Texas Presidents, focused on energy sector investments. Salazar has been involved in prior acquisition events at Comstock Resources, which brought him significant gains. The new family office keeps attention on Comstock Resources' history with high profile energy investors such as Salazar. For investors watching Comstock Resources (NYSE:CRK), the launch of Two Texas Presidents adds context around the...

Truist Financial (NYSE:TFC) is offering clients access to SEC registered spot Bitcoin ETFs through Truist Investment Services Inc. The bank has also launched open banking connectivity in partnership with Mastercard, giving clients new ways to link and manage financial data. These moves expand Truist Wealth's product shelf and introduce new digital tools for clients who want broader choice and more control. For a large US regional bank focused on retail, wealth, and commercial banking, this...

United Therapeutics has introduced a new soft mist inhaler that is positioned as a direct competitor to MannKind's Tyvaso DPI. The new device is described as offering reduced side effects, including less coughing, compared with dry powder inhalers. This development raises questions about the durability of MannKind's royalty stream from Tyvaso DPI and could influence investor expectations for NasdaqGM:MNKD. MannKind, trading on NasdaqGM:MNKD, is closely tied to royalties from Tyvaso DPI, so...

Mirion Technologies (NYSE:MIR) is facing material trade policy uncertainty after the US administration imposed new 15% global tariffs under the Trade Act of 1974. The tariffs follow a recent Supreme Court ruling and are being implemented abruptly, affecting companies with international supply chains. For Mirion, the policy shift raises questions around cost structure, operational planning, and future financial results. Mirion Technologies, trading at $21.49, now sits at the center of a...

In February 2026, Select Medical Holdings Corporation reported mixed fourth-quarter and full-year 2025 results, with revenue rising to US$1,396.63 million for the quarter and US$5,452.83 million for the year, while profitability remained under pressure. On the same day, the company declared a US$0.0625 per-share cash dividend and issued 2026 guidance calling for US$5.6 billion to US$5.8 billion in revenue and fully diluted earnings per share of US$1.22 to US$1.32, framing how management sees...

Expro Group Holdings (NYSE:XPRO) has authorized a new $100 million share repurchase program. The company has secured a major multi-year contract in North Africa with an initial four-year term. Recent earnings included higher margins and free cash flow, alongside softer revenue in certain regions. Expro Group, a global energy services provider listed on the NYSE as XPRO, is active across well construction, well flow management, and subsea services. The mix of a sizable buyback authorization...

Corcept Therapeutics FY 2025 earnings snapshot Corcept Therapeutics (CORT) has wrapped up FY 2025 with Q4 revenue of US$202.1 million and basic EPS of US$0.24, alongside net income of US$25.4 million. Over the past six quarters, the company has seen revenue move from US$181.9 million in Q4 2024 to a range between US$157.2 million and US$207.6 million per quarter, while basic EPS has ranged between US$0.19 and US$0.45. With a trailing 12 month net profit margin of 13.1% compared to 20.7% a...

Pebblebrook Hotel Trust (NYSE:PEB) recently completed a $450 million senior unsecured term loan. The company used part of the proceeds to repay certain mortgages and address near term debt maturities. Management also restored full capacity on its revolving credit facility, increasing available liquidity. Pebblebrook Hotel Trust, trading at $12.24, has had mixed share performance, with a 6.0% return year to date and a 4.6% return over the past year, but weaker 3 year and 5 year returns of...

If you are wondering whether Perfect's current share price reflects its true worth, this breakdown will help you connect the recent market action to what the numbers actually say about value. Perfect's share price closed at US$1.38, with returns of a 5.5% decline over 7 days, a 17.4% decline over 30 days, a 20.2% decline year to date, a 27.7% decline over 1 year and 81.9% and 86.1% declines over 3 and 5 years. This performance sits against a backdrop of ongoing market attention on software...

ONEOK (NYSE:OKE) reported double digit net income and adjusted EBITDA growth for 2025. The company exceeded synergy targets from recent acquisitions, including Magellan, and retired a significant amount of long term debt. ONEOK raised its quarterly dividend by 4% and continued integrating acquired assets through 2025. Management outlined plans for 2026 that include expansion into fee based earnings and energy solutions for data centers. ONEOK is a large midstream operator focused on natural...

Kiniksa Pharmaceuticals International (KNSA) closed FY 2025 with Q4 revenue of US$202.1 million and basic EPS of US$0.19, alongside net income of US$14.2 million. On a trailing twelve month basis, revenue was US$677.6 million with basic EPS of US$0.80 and net income of US$59.0 million. The company’s quarterly revenue moved from US$122.5 million and a basic EPS loss of US$0.12 in Q4 2024 to US$202.1 million and basic EPS of US$0.19 in Q4 2025. Over the same period, trailing twelve month net...

What Avidity Biosciences’ Recent Returns Signal for Investors Avidity Biosciences (RNA) has drawn attention after a 1 day return close to flat, modest moves over the past week and month, and a very large total return over the past year. For investors, those figures sit alongside a revenue base of US$18.755 million and a reported net loss of US$684.631 million. This highlights that the company remains firmly in a development focused phase. See our latest analysis for Avidity Biosciences. With...

Day One Biopharmaceuticals (DAWN) just reported its FY 2025 numbers, with Q4 total revenue of US$53.7 million and a net loss of US$21.3 million, setting the tone for how investors will read the year as a whole. The company has seen quarterly revenue move from US$29.2 million in Q4 2024 to US$53.7 million in Q4 2025, while Basic EPS shifted from a loss of US$0.64 per share in Q4 2024 to a loss of US$0.19 per share in Q3 2025, giving investors a clear view of how top line scale and loss levels...